BG64349B1 - Лечебни и хранителни състави, съдържащи незаменими мастни киселини и биоактивни дисулфиди - Google Patents
Лечебни и хранителни състави, съдържащи незаменими мастни киселини и биоактивни дисулфиди Download PDFInfo
- Publication number
- BG64349B1 BG64349B1 BG104141A BG10414100A BG64349B1 BG 64349 B1 BG64349 B1 BG 64349B1 BG 104141 A BG104141 A BG 104141A BG 10414100 A BG10414100 A BG 10414100A BG 64349 B1 BG64349 B1 BG 64349B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- acid
- gla
- vitamin
- diabetes
- fatty acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9715444A GB9715444D0 (en) | 1997-07-22 | 1997-07-22 | Therapeutic and dietary compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BG64349B1 true BG64349B1 (bg) | 2004-11-30 |
Family
ID=10816266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG104141A BG64349B1 (bg) | 1997-07-22 | 2000-02-08 | Лечебни и хранителни състави, съдържащи незаменими мастни киселини и биоактивни дисулфиди |
Country Status (31)
Country | Link |
---|---|
US (1) | US6630157B1 (de) |
EP (2) | EP1419769A1 (de) |
JP (1) | JP4476479B2 (de) |
KR (1) | KR100545630B1 (de) |
CN (2) | CN1198608C (de) |
AT (1) | ATE262900T1 (de) |
AU (1) | AU739876B2 (de) |
BG (1) | BG64349B1 (de) |
BR (1) | BR9812102A (de) |
CA (1) | CA2297082C (de) |
CZ (1) | CZ298527B6 (de) |
DE (1) | DE69822832T2 (de) |
DK (1) | DK0994705T3 (de) |
ES (1) | ES2214717T3 (de) |
GB (2) | GB9715444D0 (de) |
HK (1) | HK1029281A1 (de) |
HU (1) | HU226673B1 (de) |
IL (2) | IL134090A0 (de) |
MY (1) | MY127930A (de) |
NO (1) | NO327173B1 (de) |
NZ (1) | NZ502278A (de) |
PL (1) | PL194059B1 (de) |
PT (1) | PT994705E (de) |
RO (1) | RO121318B1 (de) |
RU (1) | RU2205004C2 (de) |
SK (1) | SK285836B6 (de) |
TR (1) | TR200000178T2 (de) |
TW (1) | TW565444B (de) |
UA (1) | UA66363C2 (de) |
WO (1) | WO1999004782A1 (de) |
ZA (1) | ZA986480B (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
DE10027968A1 (de) * | 2000-06-08 | 2001-12-13 | Asta Medica Ag | Mittel zur Therapie von Demenzen |
US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
US8669282B2 (en) * | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
DE10125882B4 (de) * | 2001-05-28 | 2007-03-29 | Esparma Gmbh | Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US6974592B2 (en) * | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
CA2499501A1 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
BR0314799A (pt) * | 2002-09-27 | 2005-07-26 | Market Biosciences Corp | Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico |
KR101175774B1 (ko) * | 2002-11-04 | 2012-08-21 | 오션 뉴트리션 캐나다 리미티드 | 다중 쉘을 갖는 마이크로캡슐 및 이의 제조 방법 |
US20060233863A1 (en) | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
JP2006519229A (ja) | 2003-02-13 | 2006-08-24 | アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ | 視床下部内の長鎖脂肪アシルCoAレベルの変調による摂食量およびグルコース産生量の調節 |
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
US8633247B2 (en) | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
US8633246B2 (en) | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Omega-3 fatty acids for osteoarthritis |
CA2529749C (en) * | 2003-08-11 | 2012-03-20 | Hill's Pet Nutrition, Inc. | Omega-3 fatty acids for the treatment of canine osteoarthritis |
EP1660071A1 (de) * | 2003-08-18 | 2006-05-31 | Btg International Limited | Behandlung von neurodegenerativen erkrankungen |
US20050261367A1 (en) * | 2004-03-29 | 2005-11-24 | Howard Murad | Methods for treating dermatological and other health-related conditions in a patient |
CA2580313C (en) * | 2004-07-19 | 2016-03-15 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
JP5118965B2 (ja) | 2004-08-10 | 2013-01-16 | エンジモテック リミテッド | 植物成分を必要とする治療方法 |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
GB0428166D0 (en) * | 2004-12-23 | 2005-01-26 | Efamol Ltd | Use of essentially fatty acid molecules |
US8034450B2 (en) * | 2005-01-21 | 2011-10-11 | Ocean Nutrition Canada Limited | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US20080139649A1 (en) * | 2005-01-27 | 2008-06-12 | Barrow Colin J | Fatty Acid-Benzenediol Derivatives and Methods of Making and Using Thereof |
US20080206316A1 (en) * | 2005-01-27 | 2008-08-28 | Colin Barrow | Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
US9968120B2 (en) * | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
US20070082063A1 (en) * | 2005-10-11 | 2007-04-12 | Douglas Bibus | Risk assessment and correction of membrane damage of the upper GI tract |
WO2007064871A2 (en) * | 2005-12-02 | 2007-06-07 | Howard Murad | Diagnostic and treatment regimen for achieving body water homeostasis |
WO2007089685A2 (en) * | 2006-01-30 | 2007-08-09 | University Of Georgia Research Foundation | Compositions and methods for inducing adipose tissue cell death |
JP2009533490A (ja) * | 2006-04-07 | 2009-09-17 | オーシャン ニュートリッション カナダ リミテッド | 低い界面張力を有する物質を含む乳濁液およびマイクロカプセル、ならびにそれらを作製および使用する方法 |
NZ596403A (en) * | 2006-06-05 | 2013-02-22 | Ocean Nutrition Canada Ltd | Microcapsules with improved shells with wax in the outer shell |
CN101641087B (zh) | 2007-01-10 | 2013-08-21 | 加拿大海洋营养食品有限公司 | 素食的微胶囊 |
DE102007038849A1 (de) | 2007-08-16 | 2009-02-19 | Adscil Gmbh | Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie |
BRPI0818004B8 (pt) | 2007-10-16 | 2021-05-25 | Biocon Ltd | composição farmacêutica sólida administrável por via oral e o processo da mesma. |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
US9119826B2 (en) * | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US9220702B2 (en) | 2011-05-12 | 2015-12-29 | Nippon Suisan Kaisha, Ltd. | Composition for external use on skin for inflammatory diseases |
US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
WO2014151128A1 (en) * | 2013-03-15 | 2014-09-25 | Andrade Agustin | Composition and method for treating neuropathy |
US9241923B2 (en) | 2013-07-16 | 2016-01-26 | Mead Johnson Nutrition Company | Methods for promoting neuronal development and/or health |
US9226914B2 (en) * | 2013-07-16 | 2016-01-05 | Mead Johnson Nutrition Company | Methods for promoting neuronal development and/or health |
CN109232278A (zh) | 2013-11-15 | 2019-01-18 | Ds生物制药有限公司 | 多不饱和羟基脂肪酸的药学上可接受的盐 |
HUE055277T2 (hu) | 2013-12-04 | 2021-11-29 | Nippon Suisan Kaisha Ltd | Dihomo-gamma-linolénsavat tartalmazó mikrobális olaj és dihomo-gamma-linolénsavat tartalmazó mikrobális biomassza |
KR102391827B1 (ko) | 2014-06-04 | 2022-04-27 | 디에스 바이오파마 리미티드 | Dgla를 포함하는 약제학적 조성물 및 그의 용도 |
WO2016044167A1 (en) * | 2014-09-15 | 2016-03-24 | Abbott Laboratories | Methods for increasing muscle strength and mobility in subjects experiencing significant physical inactivity using gamma linolenic acid |
ES2851525T3 (es) | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
WO2022140279A1 (en) * | 2020-12-22 | 2022-06-30 | Buck Institute For Research On Aging | Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies |
CN114533715A (zh) * | 2022-01-28 | 2022-05-27 | 上海市肺科医院 | 一种针对sting靶点的小分子抑制剂及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0218460A2 (de) * | 1985-10-02 | 1987-04-15 | Efamol Holdings Plc | Verwendung von gamma-Linolensäure und verwandten Verbindungen zur Herstellung eines Arneimittels zur Behandlung von Komplikationen bei Diabetes mellitus. |
WO1996034855A1 (en) * | 1995-05-01 | 1996-11-07 | Scotia Holdings Plc | Fatty acid esters as bioactive compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1176916B (it) * | 1984-10-10 | 1987-08-18 | Elvira Pistolesi | Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica |
LU86220A1 (de) | 1985-12-19 | 1987-07-24 | Chimicasa Gmbh | Verfahren zur herstellung eines den cholesterin-und triglyceridgehalt senkenden pharmazeutischen praeparates |
DE3615710A1 (de) * | 1986-05-09 | 1987-11-26 | Hoechst Ag | Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen |
US4937265A (en) * | 1987-05-28 | 1990-06-26 | Teijin Limited | Antidiabetic method comprising 7-thiaprostaglandin E1 or its derivatives |
EP0382066A3 (de) | 1989-02-09 | 1992-01-08 | ASTA Medica Aktiengesellschaft | Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum |
US5602183A (en) * | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
US5569670A (en) * | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
DE4229914A1 (de) | 1992-09-08 | 1994-03-10 | Basf Ag | Verbessertes Verfahren zur Herstellung von R/S-Ï-Liponsäure oder R/S-â-Liponsäure |
DK0661051T3 (da) * | 1993-10-11 | 2006-05-22 | Viatris Gmbh | Medikament til behandling af hypertension |
US5472698A (en) * | 1994-12-20 | 1995-12-05 | Elizabeth Arden Co., Division Of Conopco, Inc. | Composition for enhancing lipid production in skin |
WO1998033494A1 (en) * | 1997-02-04 | 1998-08-06 | Kosbab John V | Compositions and methods for prevention and treatment of vascular degenerative diseases |
IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
-
1997
- 1997-07-22 GB GB9715444A patent/GB9715444D0/en active Pending
-
1998
- 1998-07-21 ZA ZA986480A patent/ZA986480B/xx unknown
- 1998-07-22 ES ES98935163T patent/ES2214717T3/es not_active Expired - Lifetime
- 1998-07-22 DK DK98935163T patent/DK0994705T3/da active
- 1998-07-22 AT AT98935163T patent/ATE262900T1/de not_active IP Right Cessation
- 1998-07-22 RO ROA200000052A patent/RO121318B1/ro unknown
- 1998-07-22 PT PT98935163T patent/PT994705E/pt unknown
- 1998-07-22 CN CNB988075504A patent/CN1198608C/zh not_active Expired - Fee Related
- 1998-07-22 NZ NZ502278A patent/NZ502278A/en not_active IP Right Cessation
- 1998-07-22 TW TW087111948A patent/TW565444B/zh not_active IP Right Cessation
- 1998-07-22 KR KR1020007000719A patent/KR100545630B1/ko not_active IP Right Cessation
- 1998-07-22 TR TR2000/00178T patent/TR200000178T2/xx unknown
- 1998-07-22 GB GB9816020A patent/GB2327347B/en not_active Revoked
- 1998-07-22 US US09/463,300 patent/US6630157B1/en not_active Expired - Lifetime
- 1998-07-22 UA UA2000010521A patent/UA66363C2/uk unknown
- 1998-07-22 PL PL98338219A patent/PL194059B1/pl unknown
- 1998-07-22 EP EP03027639A patent/EP1419769A1/de not_active Withdrawn
- 1998-07-22 JP JP2000503839A patent/JP4476479B2/ja not_active Expired - Fee Related
- 1998-07-22 EP EP98935163A patent/EP0994705B1/de not_active Expired - Lifetime
- 1998-07-22 MY MYPI98003347A patent/MY127930A/en unknown
- 1998-07-22 CN CNA2005100095125A patent/CN1679532A/zh active Pending
- 1998-07-22 CA CA002297082A patent/CA2297082C/en not_active Expired - Fee Related
- 1998-07-22 DE DE69822832T patent/DE69822832T2/de not_active Expired - Lifetime
- 1998-07-22 CZ CZ20000229A patent/CZ298527B6/cs not_active IP Right Cessation
- 1998-07-22 IL IL13409098A patent/IL134090A0/xx active IP Right Grant
- 1998-07-22 AU AU84519/98A patent/AU739876B2/en not_active Ceased
- 1998-07-22 WO PCT/GB1998/002155 patent/WO1999004782A1/en active IP Right Grant
- 1998-07-22 BR BR9812102-2A patent/BR9812102A/pt not_active Application Discontinuation
- 1998-07-22 RU RU2000104121/14A patent/RU2205004C2/ru not_active IP Right Cessation
- 1998-07-22 SK SK84-2000A patent/SK285836B6/sk not_active IP Right Cessation
- 1998-07-22 HU HU0002701A patent/HU226673B1/hu not_active IP Right Cessation
-
2000
- 2000-01-17 IL IL134090A patent/IL134090A/en not_active IP Right Cessation
- 2000-01-21 NO NO20000303A patent/NO327173B1/no not_active IP Right Cessation
- 2000-02-08 BG BG104141A patent/BG64349B1/bg unknown
-
2001
- 2001-01-04 HK HK01100090A patent/HK1029281A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0218460A2 (de) * | 1985-10-02 | 1987-04-15 | Efamol Holdings Plc | Verwendung von gamma-Linolensäure und verwandten Verbindungen zur Herstellung eines Arneimittels zur Behandlung von Komplikationen bei Diabetes mellitus. |
WO1996034855A1 (en) * | 1995-05-01 | 1996-11-07 | Scotia Holdings Plc | Fatty acid esters as bioactive compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG64349B1 (bg) | Лечебни и хранителни състави, съдържащи незаменими мастни киселини и биоактивни дисулфиди | |
EP1296670B1 (de) | Therapeutische kombinationen von fettsäuren | |
US5116624A (en) | Efa compositions and therapy | |
EP3445355A1 (de) | Verabreichung von butyrat, beta-hydroxybutyrat und verwandten verbindungen beim menschen | |
US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
SK14502003A3 (en) | Coenzyme Q and eicosapentaenoic acid | |
IE891819L (en) | Essential fatty acid compositions | |
CA2104567A1 (en) | Fatty acid treatment | |
JP2012211147A (ja) | Epa及びdhaの少なくとも1つ又はこれらのいずれかの組み合わせを含む脂肪酸組成物の使用 | |
JPS6216415A (ja) | 月経前症候群治療用医薬組成物およびその治療方法 | |
US20220362188A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
MXPA00000793A (en) | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides | |
JPH11343236A (ja) | 多価不飽和脂肪酸を含有する医薬組成物および健康食品 |